LianBio Beheer

Beheer criteriumcontroles 2/4

De CEO LianBio is Adam Stone, benoemd in Dec2023, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.016% van de aandelen van het bedrijf, ter waarde $ 4.95K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 3.1 jaar.

Belangrijke informatie

Adam Stone

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.1yrs

Recente managementupdates

Recent updates

CEO

Adam Stone (44 yo)

less than a year

Tenure

US$62,073

Compensatie

Mr. Adam Leo Stone is Chief Investment Officer & Head of Research of Perceptive Advisors LLC. He joined the Perceptive Advisors LLC in 2006. He serves as CEO & Director at Perceptive Capital Solutions Corp...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Konstantin Poukalov	Founder & Executive Chairman	5.1yrs	US$62.07k	0.016% $ 5.0k
Adam Stone	Interim CEO & Director	less than a year	US$62.07k	0.016% $ 5.0k
Ehong Gu	Interim CFO	less than a year	geen gegevens	geen gegevens
Ji Chen	Senior VP & General Counsel	no data	geen gegevens	geen gegevens
Brianne Jahn	Chief Business Officer	3.2yrs	US$2.69m	geen gegevens
Levvy Lv Eng	Senior VP & Global Head of Development	no data	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

40yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LIAN.Y wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Konstantin Poukalov	Founder & Executive Chairman	5.1yrs	US$62.07k	0.016% $ 5.0k
Adam Stone	Interim CEO & Director	5.1yrs	US$62.07k	0.016% $ 5.0k
Tassos Anastasios Gianakakos	Independent Director	4.3yrs	US$128.07k	0.34% $ 105.4k
Susan Silbermann	Independent Director	3.1yrs	US$121.44k	0.016% $ 5.0k
Neil Kumar	Director	5.1yrs	geen gegevens	0% $ 0
Elliott Levy	Member of Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens
Mathias Hukkelhoven	Member of Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens
Wei Chen	Independent Director	2.6yrs	US$285.89k	0% $ 0
Zhao Yan	Member of Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LIAN.Y wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

LianBio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd